Banque Pictet & Cie 13F: Cuts BSX Stake by $30M
The institutional investor reduced its stake in the medical device maker by over 690,000 shares during the quarter.
Reviewed by automated data checks against the source filing. How we make and check alerts
Banque Pictet & Cie sold 694,882 shares from its stake in Boston Scientific Corporation ($BSX), a 65.04% decrease, according to a 13F filing with the SEC dated October 16, 2026. It reported 373,583 shares worth $16.31 million at the end of the quarter.
Find the original: Banque Pictet & Cie 13F filings on SEC EDGAR
BSX
Boston Scientific Corporation
Key Points
- Banque Pictet & Cie cut its Boston Scientific Corporation holdings by 65.0% during the period, lowering its stake from 1,068,465 to 373,583 shares.
- Other major funds adjusted their positions differently, with Primecap Management adding 17.9 million shares while FMR reduced its holdings.
- Boston Scientific trades with a trailing P/E ratio of 17.9 and is preparing to report its upcoming financial results on October 28, 2026.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Banque Pictet & Cie filed a Form 13F with the SEC on October 16, 2026, revealing a reduced stake in Boston Scientific Corporation (NYSE: BSX). Because 13F filings look backward at the previous quarter, this update shows the fund's holdings at that time and may not match its current portfolio.
Inside Banque Pictet & Cie's Boston Scientific Trade
Banque Pictet & Cie cut its position by 694,882 shares, resulting in a 65.0% decrease from the previous quarter. The fund finished the period with 373,583 shares valued at $16,306,898.
Other Institutional Activity in Boston Scientific
Major institutional investors made notable adjustments to their Boston Scientific holdings during the same reporting window. Blackrock Inc. trimmed its stake by 2,135,425 shares to end with 129,680,916 shares worth about $5,756,535,782. Vanguard Capital Management LLC grew its holdings by 674,889 shares, ending with 97,087,553 shares worth about $4,309,716,418. State Street Corporation added 2,121,285 shares for a 3.1% increase, holding 70,111,196 shares valued at $3,112,235,947. Primecap Management Company boosted its position significantly by 17,991,834 shares, a 55.3% jump to reach 50,520,914 shares worth $2,242,623,341. Meanwhile, FMR, LLC cut its stake by 28,526,236 shares, a 38.4% reduction that left it with 45,702,845 shares valued at $2,028,749,261.
Boston Scientific Corporation Stock Up 2.8%
Boston Scientific shares recently traded around $44.20, sitting below both their 50-day and 200-day moving averages.
Recent Earnings
Boston Scientific reported $21.0 billion in trailing-twelve-month revenue alongside earnings of $2.47 per share. The company holds a profit margin of 17.5% and a return on equity of 15.3%. Its next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Company insiders were active ahead of the filing, with CEO Michael F. Mahoney buying 186,240 shares on August 3, 2026, for about $9.0 million. Director David C. Habiger bought 1,182 shares on August 4, 2026, followed by another purchase of 2,100 shares on August 5, 2026, worth nearly $100,000. Director Susan E. Morano also picked up 2,040 shares on August 25, 2026, at an average price of $49.22.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. Oppenheimer maintained an Outperform rating on September 21, 2026, while lowering its target to $65.00. Wells Fargo kept an Equal-Weight rating with a $48.00 target on September 24, 2026. Citigroup maintained a Neutral rating with a $48.00 target on October 5, 2026. Barclays initiated coverage with an Equal-Weight rating and a $48.00 target on October 7, 2026, and Truist Securities maintained a Buy rating while trimming its target to $51.00 on October 14, 2026.
About Boston Scientific
Boston Scientific Corporation designs and builds medical devices used in interventional medical specialties across the globe. Headquartered in Marlborough, Massachusetts, the firm operates through MedSurg and Cardiovascular segments to supply hospitals and clinics with specialized healthcare technology.
Bottom Line
Investors will look toward the upcoming October 28 earnings release for fresh details on revenue and product demand. Institutional filings only offer a snapshot of past activity and may not reflect current positions.
Related Filing Alerts
Source: Banque Pictet & Cie's 13F filing on $BSX (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Banque Pictet & Cie 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts